Ethnic differences in the prognostic utility of rheumatoid factor isotypes and anticyclic citrullinated peptides in rheumatoid arthritis patients: a cross-sectional study

REFERENCES

• Waaler E. On the occurrence of a factor in human serum acti-vating the specific agglutination of sheep blood corpuscles. AP-MIS. 2007;115(5):422–38.
   Google Scholar
• Franklin E, Holman H, Muller-Eberhard H, Kunkel H. An unu-sual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J Exp Med. 1957; 105(5):425–38.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Schellekens GA, Jong BAW, Hoogen FHJ, Putte LBA, Venrooij WJ. Citrulline is an essential constituent of antigenic determi-nants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101(1):273–81.
   Google Scholar
• Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797–808.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62: 2569–81.
   PubMed Web of Science ®Google Scholar
• Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis. 2005;64(2):196–201.
   PubMed Web of Science ®Google Scholar
• Houssien DA, Jonsson T, Davies E, Scott DL. Rheumatoid factor isotypes, disease activity and the outcome of rheumatoid arthritis: comparative effects of different antigens. Scand J Rheumatol. 1998;27(1):46–53.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol. 2007;26(2):201–4.
   Google Scholar
• Vittecoq 0, Pouplin S, Krzanowska K, Jouen-Beades F, Menard JF, Gayet A, et al. Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. Rheumatol-ogy. 2003;42(8):939–46.
   Google Scholar
• Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radio-graphic progression over the first years of disease. Rheumatology. 2007;46(2):342–9.
   PubMed Web of Science ®Google Scholar
• Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Br Med J. 2003; 62(5):427–30.
   Google Scholar
• Boire G, Cossette P, de Brum-Fernandes AJ, Liang P, Niyon-senga T, Zhou ZJ, et al. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther. 2005;7(3):R592–603.
   Google Scholar
• Gomez EL, Gun SC, Somnath SD, D'Souza B, Lim AL, Chinna K, et al. The prevalence of rheumatoid factor isotypes and anti-cyclic citrullinated peptides in Malaysian rheumatoid arthritis patients. Int J Rheum Dis. 2011;14(1):12–7.
   Google Scholar
• Visser H, Gelinck LB, Kampfraath AH, Breedveld FC, Hazes JM. Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis. 1996;55(3):157–61.
   Google Scholar
• Jonsson T, Thorsteinsson J, Kolbeinsson A, Jonasdottir E, Sig-fusson N, Valdimarsson H. Population study of the importance of rheumatoid factor isotypes in adults. Ann Rheum Dis. 1992; 51(7):863–8.
   PubMedGoogle Scholar
• Turesson C, Jacobsson LTH, Sturfelt G, Matteson EL, Mathsson L, Ronnelid J. Rheumatoid factor and antibodies to cyclic cit-rullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis. 2007; 66(1):59–64.
   PubMed Web of Science ®Google Scholar
• De Rycke L, Peene I, Hoffman TEA, Kruithof E, Union A, Meheus L, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifes-tations. Ann Rheum Dis. 2004;63(12):1587–93.
   PubMed Web of Science ®Google Scholar
• Mewar D, Coote A, Moore D, Marinou I, Keyworth J, Dickson M, et al. Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther. 2006;8(4): R128.
   Web of Science ®Google Scholar
• van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and dif-ferences in clinical progression of rheumatoid arthritis. Arthr Res Ther. 2005;7(5):R949–58.
   PubMed Web of Science ®Google Scholar
• Sockalingam S, Khuan CS, Sthaneshwar P. Prevalence of anti cyclic citrullinated peptide antibodies in Malaysian rheumatoid arthritis patients and its correlation with disease activity. Int J Rheum Dis. 2009;12(3):211–5.
   Google Scholar
• Serdaroglu M, Cakirbay H, Deger 0, Cengiz S, Kul S. The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int. 2008;28(10):965–70.
   Google Scholar